This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.3G4 is a monoclonal antibody that binds due to the exposure of phosphatidylserine (PS). PS is hypothesized to be on the surface ofSIVmac251 virions. The objective of this pilot experiment was to treat threeSIVmac251 infected monkeys with a chimeric version of 3G4, and three with a control antibody. In the initial phase of the pilot experiment was a repeat dose study (8 doses) at 10mg/kg, 2 animals with a chimeric 3G4 and 2 with an isotype-matched control antibody. In the second phase, four animals were used (2 from the first phase and two na ve animals) previously infected withSIVmac251 in 2004. Two of the animals were assigned to a dose escalation arm of the study and two were assigned to a dose de-escalation arm of the study. On 1/31/07 2 animals were treated with a different derivative of the3G4 antibody designated PAO. Treatment was with 50 mg/kg or 0.1 mg/kg respectively. Blood samples were taken at 0 hr, 4 hr, 8 hr, 24 hr and 48 hr post treatment to monitor plasma viral load and serum antibody concentration. The two animals in the high dose de-escalation group had adverse reactions. Additional dosing in this study has been delayed to allow follow-up on the high dose group.
Showing the most recent 10 out of 352 publications
